 |
3 Diseases |  |
1 Trial |
|
1 Trial |  |
96 News |  |
| 12» |
- || Lonasen tape (blonanserin transdermal patch) / Nitto Denko, Sumitomo Pharma
Review, Journal, Metastases: Novel therapies for nausea and vomiting in advanced illness and supportive cancer care. (Pubmed Central) - Jun 10, 2024
Isopropyl alcohol aromatherapy has been successfully used in the emergency department for nausea and vomiting with an onset to benefit more rapidly than standard antiemetics. Isopropyl alcohol prep pads can be used for home-going antiemetic therapy and as a bridge to treating acute nausea until standard antiemetics take effect.
- | blonanserin / Generic mfg.
Journal: Improvement of social functioning in patients with first-episode schizophrenia using blonanserin treatment: a prospective, multi-centre, single-arm clinical trial. (Pubmed Central) - Apr 4, 2024
Blonanserin treatment exhibited favourable effects on social functioning in individuals with first-episode schizophrenia. The results suggest that blonanserin was effective treatment options for patients with schizophrenia encountering functional impairments.
- | blonanserin / Generic mfg.
Journal: Bioequivalence of Blonanserin Tablets Under Fasting and Fed Conditions in Healthy Chinese Subjects. (Pubmed Central) - Jan 3, 2024
These results indicate that the 2 blonanserin formulations were bioequivalent and well tolerated in healthy Chinese subjects. In clinical treatment, it is necessary to consider the food effect of blonanserin.
- || risperidone / Generic mfg., blonanserin / Generic mfg.
Retrospective data, Review, Journal: Efficacy and safety of blonanserin versus risperidone in the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials. (Pubmed Central) - Nov 3, 2023
The efficacy of blonanserin is similar to that of risperidone, but it is unclear whether blonanserin is more effective than risperidone at improving cognitive and social function. More high-quality studies are needed to verify the efficacy and safety of blonanserin in the future.
- || Clinical data, Journal: Prolactin Level Changes according to Atypical Antipsychotics Use: A Study Based on Clinical Data Warehouse. (Pubmed Central) - Oct 20, 2023
And we showed that there is a possibility to conduct more effective and simpler big data research using the CDW. Further studies on the subjects with controlled confounding variables and larger sample groups are needed.
- | blonanserin / Generic mfg., celecoxib oral / Generic mfg.
Journal: A preparative small-molecule mimic of liver CYP450 enzymes in the aliphatic C-H oxidation of carbocyclic N-heterocycles. (Pubmed Central) - Jul 14, 2023
Oxidations are demonstrated at low Mn(CF-PDP) loadings (2.5 to 5 mol%) on gram scales of substrate to furnish preparative amounts of oxidized products. A chemoinformatic analysis supports that Mn(CF-PDP) significantly expands the pharmaceutical chemical space accessible to small-molecule C-H oxidation catalysis.
- | blonanserin / Generic mfg.
Journal: Reduced sociability in a prenatal immune activation model: Modulation by a chronic blonanserin treatment through the amygdala-hippocampal axis. (Pubmed Central) - Jun 28, 2023
Low dose of blonanserin and haloperidol altered GABA and glutamate-related mRNA levels, the E/I ratio, and Bdnf long 3'UTR mRNA levels in the ventral hippocampus and amygdala, but did not attenuate behavioral impairments. These results strongly implicate changes in PV expression, PV(+) GABAergic interneuron density, and Bdnf long 3'UTR expression levels, particularly in the dorsal hippocampus, in the pathophysiology and treatment responses of MIA-induced schizophrenia and highlight the therapeutic potential of blonanserin for developmental stress-related schizophrenia.
- | blonanserin / Generic mfg.
Journal: Effect of Blonanserin on the Proliferation and Migration of Glioblastoma Cells. (Pubmed Central) - May 20, 2023
antagonism. The present study shows that blonanserin may serve as a seed compound for the discovery of new glioblastoma therapeutics to prevent the growth and metastasis of glioblastoma.
- | Journal: Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics. (Pubmed Central) - Mar 14, 2023
Further, patients switching to aripiprazole had a higher risk of relapse regardless of their original medication...Adverse effects on weight and lipid metabolism were observed in patients who switched to risperidone, while amisulpride improved lipid profiles. Changing schizophrenia treatment requires careful consideration of multiple variables, particularly the choice of substituted drug and the patient's baseline symptoms.
- || blonanserin / Generic mfg.
P4 data, Journal: Effectiveness and safety of blonanserin in young and middle-aged female patients with schizophrenia: data from a post-marketing surveillance. (Pubmed Central) - Feb 27, 2023
Blonanserin significantly improved the symptoms of schizophrenia in female patients aged 18-40 years; the drug was well tolerated and had a low tendency to cause metabolic side effects, including prolactin elevation in these patients. Blonanserin might be a reasonable drug for the treatment of schizophrenia in young and middle-aged female patients.
- | blonanserin / Generic mfg., clozapine / Generic mfg.
Journal: Survival of Combined Overdose with Very High Doses of Clozapine and Blonanserin: A Case Report. (Pubmed Central) - Feb 14, 2023
Blonanserin might be a reasonable drug for the treatment of schizophrenia in young and middle-aged female patients. No abstract available
- | blonanserin / Generic mfg.
Preclinical, Journal: The Influence of Blonanserin Supersaturation in Liquid and Silica Stabilised Self-Nanoemulsifying Drug Delivery Systems on In Vitro Solubilisation. (Pubmed Central) - Jan 22, 2023
Solidifying SNEDDS with silica enables the fabrication of powdered formulations with higher blonanserin loading and greater stability than liquid super-SNEDDS, however at the expense of drug solubilisation. These competing parameters need careful consideration in designing optimal super-SNEDDS for pre-clinical and clinical application.
- blonanserin / Generic mfg.
Behavioural and molecular effects of the antipsychotic drug blonanserin in the chronic mild stress model (Poster area [IN-PERSON]) - Oct 13, 2022 - Abstract #ECNP2022ECNP_541;
These competing parameters need careful consideration in designing optimal super-SNEDDS for pre-clinical and clinical application. Our data provide new insights into the therapeutic properties and potential use of blonanserin and provide further support for the role of oxidative stress in mediating the link between chronic stress exposure and the etiology of psychiatric disorders.
- || blonanserin / Generic mfg.
P4 data, Journal: Safety and Effectiveness of Blonanserin in Chinese Patients with Schizophrenia: An Interim Analysis of a 12-Week Open-Label Prospective Multi-Center Post-marketing Surveillance. (Pubmed Central) - Sep 7, 2022
53.5% (545/1,018) patients showed response to blonanserin treatment in week 12. The post-marketing surveillance results of BNS demonstrates safety profile and effectiveness of the drug.
- | Lonasen tape (blonanserin transdermal patch) / Nitto Denko, Sumitomo Dainippon
Observational data, Retrospective data, Journal: Acceptability of transdermal antipsychotic patches by patients who refuse oral medication and their effectiveness in preventing recurrence of delirium: a retrospective observational study. (Pubmed Central) - Aug 22, 2022
Instead, a transdermal patch of blonanserin, a second-generation antipsychotic drug, was tried...The present findings suggest that transdermal antipsychotic patches are more likely to be accepted by patients who refuse oral medications. Prospective studies are needed.
- | blonanserin / Generic mfg.
Journal: Case report of bradycardia induced by blonanserin in schizophrenia. (Pubmed Central) - May 15, 2022
Prospective studies are needed. No abstract available
- | blonanserin / Generic mfg.
Clinical protocol, Journal: Effectiveness and safety of blonanserin for improving social and cognitive functions in patients with first-episode schizophrenia: a study protocol for a prospective, multicentre, single-arm clinical trial. (Pubmed Central) - Apr 28, 2022
P4
The study will be conducted according to the principles of the Declaration of Helsinki and follow the principles for clinical research. NCT03784222.
- || blonanserin / Generic mfg.
PK/PD data, Preclinical, Journal: A Simple and Sensitive HPLC-MS/MS Assay for the Quantitation of Blonanserin and N-Desethyl Blonanserin in Rat Plasma and Its Application to Pharmacokinetic Study. (Pubmed Central) - Apr 19, 2022
The lower limit of quantification (LLOQ), calibration curves, carryover, and matrix effects were sufficiently accurate and precise according to the National Medical Products Administration (NMPA) guidelines for bioanalytical method validation. This analytical method was successfully applied in a blonanserin-poloxamer thermosensitive gel pharmacokinetic study in rats.
- | aripiprazole / Generic mfg., olanzapine / Generic mfg., blonanserin / Generic mfg.
Journal: Subthreshold Change in Glycated Hemoglobin and Body Mass Index After the Initiation of Second-Generation Antipsychotics Among Patients With Schizophrenia or Bipolar Disorder: A Nationwide Prospective Cohort Study in Japan. (Pubmed Central) - Apr 12, 2022
Our results suggest that blonanserin is likely to be a favorable treatment for patients with high risk of diabetes. Trial Registration: UMIN Clinical Trial Registry identifier: UMIN000009868.
- || blonanserin / Generic mfg.
Clinical, Journal: Long-Term Safety and Efficacy of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 52-Week, Multicenter, Open-Label Extension Study. (Pubmed Central) - Mar 18, 2022
There were no major issues with the safety or tolerability of blonanserin administration in this study. Considering relatively less adverse effects on weight increase and metabolic parameters, blonanserin is expected to be a safe/tolerable treatment option for adolescent schizophrenia that can be used seamlessly from adolescence to adulthood.
- || haloperidol / Generic mfg., blonanserin / Generic mfg.
Clinical, Journal: Improved response to electroconvulsive therapy after switching from haloperidol to blonanserin in a case with treatment-resistant schizophrenia. (Pubmed Central) - Mar 18, 2022
Considering relatively less adverse effects on weight increase and metabolic parameters, blonanserin is expected to be a safe/tolerable treatment option for adolescent schizophrenia that can be used seamlessly from adolescence to adulthood. No abstract available
- | blonanserin / Generic mfg.
Journal: Efficacy and Safety of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study. (Pubmed Central) - Mar 18, 2022
Blonanserin achieved a sufficient efficacy in adolescent patients, and the safety profile was similar to that in adults, which suggests that blonanserin may be a safe treatment option for adolescents with schizophrenia. Study registration number: Japic CTI-111724.
- | blonanserin / Generic mfg.
Journal: The type rather than the daily dose or number of antipsychotics affects the incidence of hyperglycemic progression. (Pubmed Central) - Feb 25, 2022
Furthermore, changes in HbA1c levels 6 mo after the initiation of zotepine treatment were significantly higher than those following blonanserin and haloperidol treatments...Our study indicated that the type of antipsychotic had a greater affect on the incidence of hyperglycemic progression than the daily dose of antipsychotics or their number. Among these, zotepine was most likely to increase the incidence of hyperglycemic progression, suggesting the need for caution when these antipsychotics are prescribed.
- || blonanserin / Generic mfg.
Clinical, Journal: Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second-generation antipsychotics: 52-week evaluation of JUMPs, a randomized, open-label study. (Pubmed Central) - Jan 27, 2022
Among these, zotepine was most likely to increase the incidence of hyperglycemic progression, suggesting the need for caution when these antipsychotics are prescribed. All three SGAs evaluated in this study showed similar treatment discontinuation rates in patients with chronic schizophrenia in Japan.
- blonanserin / Generic mfg.
Long-Term Safety And Efficacy Of Blonanserin Oral Tablet (Dsp-5423) In Adolescents With Schizophrenia: A 52-Week, Multicenter, Open-Label, Extension Study () - Dec 18, 2021 - Abstract #AACAP2021AACAP_841;
There were no major issues with the safety or tolerability of BNS administration. Considering relatively fewer adverse effects on weight increase and metabolic parameters, BNS is expected to be a safe/tolerable treatment option for adolescent schizophrenia.SZ, APS, PPC
- | Rexulti (brexpiprazole) / Lundbeck, Otsuka
Preclinical, Journal: Inhibitory Effects of Antipsychotics on the Contractile Response to Acetylcholine in Rat Urinary Bladder Smooth Muscles. (Pubmed Central) - Dec 16, 2021
The remaining nine antipsychotics (pipamperone (a butyrophenone), sulpiride, sultopride, tiapride, nemonapride (benzamides), risperidone, paliperidone (SDAs), aripiprazole, and brexpiprazole (dopamine partial agonists)) did not inhibit ACh-induced contractions at concentrations up to 10 M. These findings suggest that chlorpromazine, levomepromazine, zotepine, olanzapine, quetiapine, and clozapine should be avoided by elderly people with urinary disorders.
- | blonanserin / Generic mfg.
Journal: Behavioral and molecular effects of the antipsychotic drug blonanserin in the chronic mild stress model. (Pubmed Central) - Nov 21, 2021
Our results demonstrated that the antipsychotic treatment normalizes the CMS-induced emotionality deficits, an effect that may be due to its ability in modulating, within the prefrontal cortex, redox mechanisms, a molecular dysfunction associated with several psychiatric disorders. These evidences provide new insights in the therapeutic properties and potential use of blonanserin as well as in its mechanisms of action and provide further support for the role of oxidative stress in the pathophysiology of psychiatric disorders.
- || blonanserin / Generic mfg.
Review, Journal: Long-term oral blonanserin treatment for schizophrenia: a review of Japanese long-term studies. (Pubmed Central) - Sep 9, 2021
Blonanserin might represent a promising treatment option that partially or completely relieves patients with chronic schizophrenia of polypharmacy. Blonanserin may possibly fit both the current real-world clinical setting and the currently recommended approach to antipsychotic medication.
- || Clinical, Journal, HEOR, Real-world evidence: Characteristics of discharge prescriptions for patients with schizophrenia or major depressive disorder: Real-world evidence from the Effectiveness of Guidelines for Dissemination and Education (EGUIDE) psychiatric treatment project. (Pubmed Central) - Aug 19, 2021
Our results showed the use of high doses of antipsychotics, high percentages of antipsychotic polypharmacy and concurrent use of hypnotics/anxiolytics in patients with schizophrenia. Notably, these data were collected before intensive instruction regarding the guidelines; therefore, we need to assess the change in the prescription pattern post guideline instruction.
- || olanzapine / Generic mfg., blonanserin / Generic mfg.
Clinical, Journal: A randomized-controlled trial of blonanserin and olanzapine as adjunct to antipsychotics in the treatment of patients with schizophrenia and dopamine supersensitivity psychosis: The ROADS study. (Pubmed Central) - Jun 22, 2021
The concomitant antipsychotic doses were reduced in both groups with good tolerability. Our results suggest that augmentations with BNS and OLZ are antipsychotic treatment options for DSP patients, and BNS may be favorable for DSP based on the relatively quick responses to BNS observed herein.
- | blonanserin / Generic mfg.
Preclinical, Journal: The Influence of Solidification on the in vitro Solubilisation of Blonanserin Loaded Supersaturated Lipid-Based Oral Formulations. (Pubmed Central) - Jun 22, 2021
Liquid SNEDDS were identified as the optimal oral supersaturated LBF strategy for BLON based on in vitro lipolysis studies. Solidification of LBF using silica is a viable strategy for improving stability, however for drugs such as BLON, solidification may impede in vitro release and solubilisation.
- ||| risperidone / Generic mfg., blonanserin / Generic mfg.
Clinical, P3 data, Retrospective data, Journal: Blonanserin vs risperidone in Japanese patients with schizophrenia: A post hoc analysis of a phase 3, 8-week, multicenter, double-blind, randomized controlled study. (Pubmed Central) - May 29, 2021
Blonanserin exerted the similar efficacy to risperidone in both positive and negative symptoms in schizophrenia with a lower risk of prolactin increase, weight gain, and orthostatic hypotension compared with risperidone. Blonanserin will serve as a favorable treatment option for schizophrenia in daily clinical practice.
- || blonanserin / Generic mfg.
Clinical, Journal: Evaluation of dopamine D receptor occupancy by blonanserin using [C]-(+)-PHNO in schizophrenia patients. (Pubmed Central) - May 20, 2021
Blonanserin will serve as a favorable treatment option for schizophrenia in daily clinical practice. Our study confirmed that blonanserin occupied both D and D receptors in patients with schizophrenia.
- | blonanserin / Generic mfg.
Journal: Refractory dry eye disease associated with Meige's syndrome induced by long-term use of an atypical antipsychotic. (Pubmed Central) - May 15, 2021
Our study confirmed that blonanserin occupied both D and D receptors in patients with schizophrenia. In patients with refractory dry eye disease, especially those with involuntary movements of the eyelids with oromandibular dystonia, it is important to ask about their psychotropic medications and to consider the possibility of drug-induced Meige's syndrome and discontinuation of medications, if possible.
- || blonanserin / Generic mfg.
Clinical, P4 data, Review, Journal: Safety and effectiveness of oral blonanserin for schizophrenia: A review of Japanese post-marketing surveillances. (Pubmed Central) - May 14, 2021
These results were consistent through 1-year of treatment, suggesting that effectiveness is maintained even after long-term use. In conclusion, blonanserin is considered a beneficial drug in real clinical practice for patients with schizophrenia having diverse characteristics.
- || Abilify Maintena (aripiprazole depot formulation) / Otsuka, Lundbeck
Clinical, Retrospective data, Journal: Clinical Benefit and Utility of Switching to Aripiprazole Once Monthly in Patients with Antipsychotic Polypharmacy or Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study. (Pubmed Central) - Apr 24, 2021
The present study have clearly shown the clinical benefit and utility of switching to AOM for treatment of patients with APpoly/LAIs in routine practice. Subsequent, adequately-powered, well-controlled clinical trials may be necessary to confirm our findings in near future.
- || risperidone / Generic mfg., blonanserin / Generic mfg.
Clinical, Journal, Monotherapy: Quantitative Resting State Electroencephalography in Patients with Schizophrenia Spectrum Disorders Treated with Strict Monotherapy Using Atypical Antipsychotics. (Pubmed Central) - Apr 24, 2021
Patients taking clozapine and olanzapine demonstrated significant slow wave increases...Use of any antipsychotic drug by patients was associated with a dose-dependent increase in theta power. However, each type of antipsychotic demonstrated different spectral power changes.
- || blonanserin / Generic mfg.
Clinical: Possible effect of blonanserin on gambling disorder: A clinical study protocol and a case report. (Pubmed Central) - Apr 24, 2021
This case suggests that blonanserin is potentially an effective treatment for patients with gambling disorder who resist standard therapies, but it also carries a risk of adverse effects. Further studies are needed to confirm the findings.
- ||| risperidone / Generic mfg., blonanserin / Generic mfg.
Journal, Adverse events: Effect of antipsychotics on breast tumors by analysis of the Japanese Adverse Drug Event Report database and cell-based experiments. (Pubmed Central) - Apr 2, 2021
In in vitro experiments, antipsychotics did not promote MCF-7 cell proliferation whereas blonanserin suppressed MCF-7 cell growth. Further research on the effects of blonanserin on the onset and progression of breast tumor is expected.
- blonanserin / Generic mfg.
[VIRTUAL] Safety of Oral Blonanserin for Schizophrenia: Results of a Chinese Post-Marketing Surveillance () - Mar 7, 2021 - Abstract #CINP2021CINP_167;
Blonanserin is a generally well tolerated drug that can be used in real clinical practice for patients with schizophrenia. The most common TEAEs of blonanserin was EPS.
- blonanserin / Generic mfg.
[VIRTUAL] Efficacy and Safety of Blonanserin Oral Tablet (DSP-5423) in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study () - Mar 7, 2021 - Abstract #CINP2021CINP_131;
The most common TEAEs of blonanserin was EPS. The results of this study demonstrate that blonanserin is effective in the treatment of adolescent schizophrenia and generally well tolerated.
- blonanserin / Generic mfg.
[VIRTUAL] Effectiveness of Oral Blonanserin for Schizophrenia: Results of a Chinese Post-Marketing Surveillance () - Mar 7, 2021 - Abstract #CINP2021CINP_130;
The results of this study demonstrate that blonanserin is effective in the treatment of adolescent schizophrenia and generally well tolerated. Blonanserin is a beneficial drug that can be used in real clinical practice for patients with schizophrenia, and can effectively improve the symptoms of Schizophrenia.
- || Lonasen (blonanserin) / Sumitomo Dainippon
Clinical, Journal: Catatonia associated with late-life psychosis successfully treated with lithium: a case report. (Pubmed Central) - Feb 20, 2021
Moreover, lithium may be effective for both catatonic and psychotic symptoms, as it normalizes imbalances of excitatory and inhibitory systems in the brain, which underlies major psychosis. Cumulative evidence from further cases is needed to validate our findings.
- || Lonasen (blonanserin) / Sumitomo Dainippon
Clinical, Journal: Model-based analysis of therapeutic efficacy of blonanserin and risperidone in schizophrenia patients and effects on prolactin: A randomized double-blind study. (Pubmed Central) - Feb 7, 2021
Prolactin elevations in female patients were 2.95-fold of the value in male patients administered the same drug. The model demonstrated Blonanserin has similar antischizophrenic efficacy and less serum prolactin rising compared to risperidone in Chinese patients.
- | Lonasen (blonanserin) / Sumitomo Dainippon
Clinical, Journal: Experimental analysis of the onset mechanism of TdP reported in an LQT3 patient during pharmacological treatment with serotonin-dopamine antagonists against insomnia and nocturnal delirium. (Pubmed Central) - Dec 18, 2020
These results indicate that perospirone and blonanserin may cause the hypotension-induced, reflex-mediated increase of sympathetic tone, leading to the increase of inward Ca current in the heart except that the high dose of perospirone reversed them. Thus, blonanserin may have more potential to produce intracellular Ca overload triggering early afterdepolarization than perospirone, which might explain the onset of TdP in the LQT3 patient.
- | Lonasen (blonanserin) / Sumitomo Dainippon
Journal: Chronic treatment with the antipsychotic drug blonanserin modulates the responsiveness to acute stress with anatomical selectivity. (Pubmed Central) - Oct 1, 2020
Taken together, our findings show that chronic exposure to blonanserin modulates selective IEGs with a specific anatomical profile. Moreover, the differential activation of specific brain regions under challenging conditions may contribute to specific clinical features of the drug.
- | Journal: Transdermal Delivery of Antipsychotics: Rationale and Current Status. (Pubmed Central) - Sep 23, 2020
Despite the current availability of a large number of antipsychotics, only a few of these drugs (e.g. aripiprazole, asenapine, blonanserin, chlorpromazine, haloperidol, olanzapine, prochlorperazine, quetiapine, and risperidone) have been developed as transdermal delivery systems...However, few clinical trials on transdermal delivery of antipsychotic drugs are available and only delivery systems containing asenapine and blonanserin have shown interesting clinical results in terms of pharmacokinetic data, efficacy, and tolerability. Recently, the transdermal patch formulation of blonanserin was approved in Japan for the treatment of schizophrenia.
- Lonasen (blonanserin) / Sumitomo Dainippon
[VIRTUAL] Efficacy and Safety of Blonanserin Oral Tablet (DSP-5423) in Adolescents With Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study () - Aug 29, 2020 - Abstract #AACAP2020AACAP_710;
- ||| haloperidol / Generic mfg., Lonasen (blonanserin) / Sumitomo Dainippon
Clinical, P3 data, Journal: Blonanserin versus haloperidol in Japanese patients with schizophrenia: A phase 3, 8-week, double-blind, multicenter, randomized controlled study. (Pubmed Central) - Jul 2, 2020
Blonanserin is as effective as haloperidol for the treatment of schizophrenia. Blonanserin is more effective for negative symptoms with a lower risk of extrapyramidal symptoms compared with haloperidol.
- | Lonasen (blonanserin) / Sumitomo Dainippon
Clinical, Journal: Combination treatment with guanfacine extended release and blonanserin for Tourette's Disorder comorbid with Attention-Deficit/Hyperactivity Disorder: A case report. (Pubmed Central) - Jul 2, 2020
Blonanserin is more effective for negative symptoms with a lower risk of extrapyramidal symptoms compared with haloperidol. No abstract available